Biomarin Pharmaceut (BMRN) 95.73 $BMRN
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Citi's 11 Annual Biotech Conference September 7 in Boston
BMRN: 95.73 (+0.54)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
Forbes Ranks BioMarin 10th Most Innovative Company in the World
GlobeNewswire - Wed Aug 24, 8:53AM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most Innovative Companies." This is the third consecutive year that BioMarin has received the recognition, acknowledging the company's ongoing commitment to rapidly developing and delivering first-in-class or best-in-class therapies for those with severe or life-threatening rare diseases. Last year, the company was also ranked 10, and in 2014, the company ranked 7.
BMRN: 95.73 (+0.54)
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 6.11% Rise
Comtex SmarTrend(R) - Mon Aug 22, 11:59AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $95.18 to a high of $97.97. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $94.06 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 95.73 (+0.54)
Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 9:20AM CDT
BioMarin Pharmaceutical (BMRN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
BMRN: 95.73 (+0.54)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), REGN: 388.64 (-4.76)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), MNTA: 12.30 (+0.15), REGN: 388.64 (-4.76)
After Yesterday's Decline of 3.87%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 11:50AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $93.74 to a high of $95.94. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $97.70 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 95.73 (+0.54)
BioMarin Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 09, 8:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to BioMarin from this offering are expected to be approximately $720.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioMarin. The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions. BioMarin has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. BioMarin intends to use the net proceeds from the offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to its manufacturing capability for its gene therapy program.
BMRN: 95.73 (+0.54)
BioMarin Announces Public Offering of Common Stock
GlobeNewswire - Mon Aug 08, 3:33PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock. BioMarin intends to use the net proceeds from the offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to its manufacturing capability for its gene therapy program.
BMRN: 95.73 (+0.54)
BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:34AM CDT
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
BMRN: 95.73 (+0.54), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05), SNY: 39.18 (+0.77)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 95.73 (+0.54), PFE: 34.77 (+0.09), ANIK: 47.89 (-0.05)
BioMarin Announces Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:04PM CDT
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million
BMRN: 95.73 (+0.54)
Will AVEO (AVEO) Pull a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 4:58PM CDT
AVEO Pharmaceuticals (AVEO), which is expected to report second-quarter 2016 results on Aug 8, had posted in-line results last quarter.
IPXL: 24.03 (+0.09), BMRN: 95.73 (+0.54), AVEO: 0.90 (-0.01), MYL: 39.97 (-1.95)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), GILD: 76.89 (-0.53), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), ARIA: 10.12 (-0.07), AEGN: 19.01 (+0.47)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
Is a Surprise Coming for BioMarin Pharmaceutical (BMRN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:57AM CDT
BioMarin Pharmaceutical (BMRN) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory
BMRN: 95.73 (+0.54)
Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 95.73 (+0.54), IMGN: 2.75 (-0.05)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 95.73 (+0.54), GWPH: 82.73 (+0.45), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Citi's 11 Annual Biotech Conference September 7 in Boston
BMRN: 95.73 (+0.54)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
Forbes Ranks BioMarin 10th Most Innovative Company in the World
GlobeNewswire - Wed Aug 24, 8:53AM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most Innovative Companies." This is the third consecutive year that BioMarin has received the recognition, acknowledging the company's ongoing commitment to rapidly developing and delivering first-in-class or best-in-class therapies for those with severe or life-threatening rare diseases. Last year, the company was also ranked 10, and in 2014, the company ranked 7.
BMRN: 95.73 (+0.54)
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 6.11% Rise
Comtex SmarTrend(R) - Mon Aug 22, 11:59AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $95.18 to a high of $97.97. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $94.06 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 95.73 (+0.54)
Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 9:20AM CDT
BioMarin Pharmaceutical (BMRN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
BMRN: 95.73 (+0.54)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), REGN: 388.64 (-4.76)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), MNTA: 12.30 (+0.15), REGN: 388.64 (-4.76)
After Yesterday's Decline of 3.87%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 11:50AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $93.74 to a high of $95.94. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $97.70 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 95.73 (+0.54)
BioMarin Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 09, 8:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to BioMarin from this offering are expected to be approximately $720.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioMarin. The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions. BioMarin has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. BioMarin intends to use the net proceeds from the offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to its manufacturing capability for its gene therapy program.
BMRN: 95.73 (+0.54)
BioMarin Announces Public Offering of Common Stock
GlobeNewswire - Mon Aug 08, 3:33PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock. BioMarin intends to use the net proceeds from the offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to its manufacturing capability for its gene therapy program.
BMRN: 95.73 (+0.54)
BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:34AM CDT
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
BMRN: 95.73 (+0.54), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05), SNY: 39.18 (+0.77)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 95.73 (+0.54), PFE: 34.77 (+0.09), ANIK: 47.89 (-0.05)
BioMarin Announces Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:04PM CDT
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million
BMRN: 95.73 (+0.54)
Will AVEO (AVEO) Pull a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 4:58PM CDT
AVEO Pharmaceuticals (AVEO), which is expected to report second-quarter 2016 results on Aug 8, had posted in-line results last quarter.
IPXL: 24.03 (+0.09), BMRN: 95.73 (+0.54), AVEO: 0.90 (-0.01), MYL: 39.97 (-1.95)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), GILD: 76.89 (-0.53), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), ARIA: 10.12 (-0.07), AEGN: 19.01 (+0.47)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
Is a Surprise Coming for BioMarin Pharmaceutical (BMRN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:57AM CDT
BioMarin Pharmaceutical (BMRN) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory
BMRN: 95.73 (+0.54)
Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 95.73 (+0.54), IMGN: 2.75 (-0.05)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 95.73 (+0.54), GWPH: 82.73 (+0.45), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
